No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PSTX Poseida Therapeutics
- 2.645
- -0.065-2.40%
Close May 10 16:00 ET
- 2.650
- +0.005+0.19%
Post 18:52 ET
256.38MMarket Cap-1930P/E (TTM)
2.785High2.592Low368.91KVolume2.740Open2.710Pre Close982.36KTurnover0.57%Turnover RatioLossP/E (Static)96.93MShares4.27052wk High2.47P/B170.00MFloat Cap1.54052wk Low--Dividend TTM64.27MShs Float17.620Historical High--Div YieldTTM7.12%Amplitude1.540Historical Low2.662Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
Strong Buy Rating for Poseida Therapeutics Amidst Strategic Partnerships and Robust CAR-T Manufacturing Capabilities
Strategic Advancements and Favorable Deal Terms Reinforce Buy Rating for Poseida Therapeutics
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos
Poseida Therapeutics (PSTX) and Astellas Pharma subsidiary Xyphos Biosciences have entered into a research partnership and license agreement to develop new cancer cell therapy platforms using the Xyph
Biotech Soars on Research Collaboration And License Agreement Release
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg